VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update Thursday, highlighting progress during the first half of 2026 in advancing its proprietary BiTAC(R) platform and a growing interest from potential pharmaceutical partners. The company reported that its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations.
“We are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats,” the company stated in its press release. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. For more details, the full press release is available at https://ibn.fm/xTF5q. Additional updates are also available in the company’s newsroom at http://ibn.fm/VRXA.
VERAXA’s pipeline update underscores a strategic shift toward focusing resources on its BiTAC platform, which the company believes offers a differentiated approach to T-cell engagement and ADC design. With four BiTAC-TCE programs in development, the company is positioning itself to address multiple solid tumor indications. The two bispecific ADC programs further broaden its therapeutic reach, while the non-BiTAC assets represent potential near-term monetization opportunities to extend the company’s financial runway.
Industry interest in T-cell engagers and ADCs has been robust, as evidenced by the partnering discussions at recent scientific meetings. VERAXA’s ability to leverage its BiTAC platform could lead to strategic collaborations that accelerate development and reduce financial risk. The company’s target of IND/CTA readiness for VXA-102 by early 2028 provides a clear near-term milestone for investors and partners alike.
As VERAXA continues to execute on its pipeline and partnering strategy, the coming quarters will be critical for demonstrating the platform’s potential and securing the collaborations necessary to advance its next-generation cancer therapies.
